A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., a company based in Edmonton. Aurora has formed a special committee to review the unsolicited bid from Curaleaf Holdings Inc. The potential acquisition could result in the formation of a combined cannabis entity with operations spanning 17 countries across Europe, North America, and other global markets.
Curaleaf, headquartered in Stamford, Conn., and listed on the Toronto Stock Exchange, disclosed its intention to acquire all shares of Aurora publicly after unsuccessful private negotiations with Aurora’s leadership. Despite sending formal proposals on June 23 and July 7, Aurora’s board has not actively engaged in discussions with Curaleaf, according to the latter.
Curaleaf has proposed a payment of $4 US per share to Aurora shareholders, in addition to $0.75 US in cash for each Aurora share. While Aurora confirmed receipt of the proposals, it clarified that only the July 7 letter included specific financial terms, which did not detail the cash and share breakdown.
Aurora refuted Curaleaf’s assertion that it declined to consider the offer, mentioning ongoing correspondence between the companies’ leaders until July 24. Aurora plans to establish a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests, with no guarantee of a finalized agreement at this stage.
While acknowledging Curaleaf’s interest, TD Cowen analysts Derek Lessard and Ryan Neal believe that the current offer underestimates Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, diverse product range, strong financial position, and adeptness in navigating global regulatory frameworks as factors that could drive substantial value creation in the future.
Curaleaf’s CEO, Boris Jordan, emphasized the value that a merger between the companies could unlock by leveraging Curaleaf’s global distribution network alongside Aurora’s established international medical cannabis operations and production capabilities. The combined revenue of both companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US following the acquisition.
Jordan sees the merger as beneficial for both Curaleaf and Aurora shareholders, offering an opportunity for Aurora investors to access a more diversified global platform and benefit from favorable U.S. regulatory trends.